Abstract:Natural, extracellular membrane vesicles secreted by Gram-negative bacteria, outer membrane vesicles (OMVs), contain numerous pathogen-associated molecular patterns which can activate systemic immune responses. Previous studies have shown that OMVs induce strong IFN-γ- and T cell-mediated anti-tumor effects in mice. However, IFN-γ is known to upregulate immunosuppressive factors in the tumor microenvironment, especially the immune checkpoint programmed death 1 ligand 1 (PD-L1), which may hamper T cell function and limit immunotherapeutic effectiveness. Here, we report the development of genetically engineered OMVs whose surface has been modified by insertion of the ectodomain of programmed death 1 (PD1). This genetic modification does not affect the ability of OMVs to trigger immune activation. More importantly, the engineered OMV-PD1 can bind to PD-L1 on the tumor cell surface and facilitate its internalization and reduction, thereby protecting T cells from the PD1/PD-L1 immune inhibitory axis. Through the combined effects of immune activation and checkpoint suppression, the engineered OMVs drive the accumulation of effector T cells in the tumor, which, in turn, leads to a greater impairment of tumor growth, compared with not only native OMVs but also the commonly used PD-L1 antibody. In conclusion, this work demonstrates the potential of bioengineered OMVs as effective immunotherapeutic agents that can comprehensively regulate the tumor immune microenvironment to effect markedly increased anti-tumor efficacy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c03776?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c03776</a>.Additional figures for further characterization of OMVs and OMV-PD1 (Supplementary Figure 1); BMDCs mature, TLRs response, and CD49b+ NK cells quantification (Supplementary Figures 2, 3, and 4); PD-L1 upregulation in tumor cells in response to OMVs or IFN-γ (Supplementary Figure 5); immunoprecipitation results with OMVs and OMV-PD1 (Supplementary Figure 6); cell-binding and uptake studies (Supplementary Figures 7 and 8); intracellular fate of OMVs and OMV-PD1 (Supplementary Figure 9); proportion of proliferative T cells (Supplementary Figure 10); OMV-PD1 blood retention time (Supplementary Figure 11); cytotoxicity on B16, CT26, and HUVEC (Supplementary Figure 12); B16 and CT26 tumor images and average body weight (Supplementary Figure 13); analysis of effector memory T cells (CD3+CD8+CD44+CD62L–), CD49b+ cells, and CD11b+ cells (Supplementarys Figure 14 and 15); quantification analysis of PDL1 (Supplementary Figure 16); percentage of IFN-γ+CD8+ T cells (Supplementary Figure 17); biosafety of OMVs (Supplementary Figures 18 and 19); effects of immunotherapy on organ histology (Supplementary Figure 20); and Pearson's colocalization coefficiencts (PCC) of PD-L1 and acid compartments (Supplementary Table 1) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c03776/suppl_file/nn0c03776_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy

Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy Against Metastatic Tumors

Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition

Transforming “cold” tumors into “hot” ones via tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy

Amplified cancer immunotherapy of PD-L1 blockade by sequential tumor microenvironment reshaping and DC maturation

Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l -Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade

Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD‐L1 Expression for Circumventing Immune Resistance of Cancer

PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy

Induction of therapeutic immunity and cancer eradication through biofunctionalized liposome-like nanovesicles derived from irradiated-cancer cells

In vivo activated T cell targeting with PD-1/PD-L1 blockade for sequential treatment mediated cancer immunotherapy

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody

Adaptive Design of Nanovesicles Overcoming Immunotherapeutic Limitations of Chemotherapeutic Drugs through Poliovirus Receptor Blockade

Biomimetic Nanomodulators With Synergism of Photothermal Therapy and Vessel Normalization for Boosting Potent Anticancer Immunity

Sequential Delivery of PD-1/PD-L1 Blockade Peptide and IDO Inhibitor for Immunosuppressive Microenvironment Remodeling Via an MMP-2 Responsive Dual-Targeting Liposome

Dual-responsive PEG-lipid Polyester Nanoparticles for Sirna and Vaccine Delivery Elicit Anti-Cancer Immune Responses by Modulating Tumor Microenvironment

Phytochemical Engineered Bacterial Outer Membrane Vesicles for Photodynamic Effects Promoted Immunotherapy.

Immune Checkpoint Reprogramming Via Sequential Nucleic Acid Delivery Strategy Optimizes Systemic Immune Responses for Gastrointestinal Cancer Immunotherapy

Reigniting the cancer-immunity cycle with nanoparticles for simultaneous delivery of oncolytic peptides and a TLR agonist

Stepwise Targeting and Tandem Responsive Peptide Nanoparticles Enhance Immunotherapy through Prolonged Drug Retention

The Programmed Site-Specific Delivery of LY3200882 and PD-L1 Sirna Boosts Immunotherapy for Triple-Negative Breast Cancer by Remodeling Tumor Microenvironment.